SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics ($MLTX) is trending after a massive drop following clinical trial results for its lead drug, with discussions focused on whether the market overreacted and if a significant rebound is possible. Community members are debating the drug's efficacy compared to existing treatments and speculating about potential acquisition offers, highlighting the company's cash reserves and other pipeline programs. Despite the negative news, some investors believe the sell-off was overdone, creating a buying opportunity, while others fear further declines.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its association with cannabis culture, highlighting freedom and growth. Some users are pointing to a potential connection to recent news regarding cannabis and senior healthcare. Community members are actively sharing contract addresses and expressing bullish sentiment.

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed ($WOLF) is trending due to its emergence from Chapter 11 bankruptcy, which involved restructuring and share cancellation, leading to significant price volatility. The community is actively debating the impact of the restructuring on existing shareholders and the potential for a short squeeze given the reduced float. Discussions also involve the new board appointments and the company's prospects in the silicon carbide market.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending due to a recent short report questioning the company's ARR and partnerships, sparking heated debates within the community. While some investors are concerned about the allegations and lack of reviews on Azure Marketplace, others are defending the company, citing strong institutional backing and potential for significant growth in the AI-powered commerce space. The upcoming earnings report is anticipated as a major catalyst that will either validate or disprove the claims, creating significant volatility and uncertainty around the stock.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as community members discuss recent price drops, potential support levels, and a Morgan Stanley downgrade. Some traders are concerned about overnight dumps and the stock's recent performance, while others see it as a buying opportunity, citing the company's fundamentals and potential for an oral weight loss pill. Discussions also include comparisons to competitors and speculation about future M&A activity in the weight loss drug market.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company ($ABAT) is trending due to significant price and volume surges, fueled by anticipation of a Pre-Feasibility Study (PFS) release. The community is buzzing with speculation about the PFS results and potential government funding, with many expressing long-term bullish sentiment. The stock's movement is also attributed to its potential role in the domestic battery supply chain and interest from institutional investors.

Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Applied Dna Sciences Inc

Applied DNA Sciences is trending as investors discuss its strategic shift towards a BNB-focused digital asset treasury, fueled by a recent $58M private placement. Community members are debating potential price levels and the involvement of Anthony Scaramucci as an advisor. The company's small float and potential ticker change to BNBX are also key talking points.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to a significant selloff sparked by a now-retracted LinkedIn post from an FDA official questioning the safety and efficacy of its drug, Lupkynis, which led to investor concerns and discussions around potential lawsuits and market manipulation. The community is actively debating the motivations behind the post, the company's response, and the possibility of legal action against the individual. Despite the controversy, some investors view the dip as a buying opportunity, citing the drug's strong Q2 earnings and potential buyout prospects.

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

Artelo Biosciences Inc

ARTL is trending due to positive first-in-human data for its non-opioid pain treatment candidate, ART26.12, sparking discussions around its potential in the multi-billion dollar pain therapeutics market. However, the company's history of dilution and reverse stock splits has some traders wary, while others are eyeing a potential short squeeze given the stock's low float.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

Carnival Corp is trending as the stock approaches multi-year highs, fueled by optimism around record demand, fleet optimization, and potential benefits from future interest rate cuts. Community discussions revolve around the stock's breakout potential, debt restructuring progress, and the impact of strategic initiatives like Celebration Key. Bullish sentiment is further supported by recent analyst upgrades and significant institutional investments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BlackRock Institutional Trust Company N.A. - iShares Long-Term Corporate Bond ETF

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$63.69
Prev Close	$63.55
Open	$63.57
Dividend Yield	N/A
50-Day Moving Average	$60.91
Beta	N/A
Avg. Volume	117,010.14
PE Ratio	N/A

52-Week High	$63.61
52-Week Low	$55.00
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

IGLB
iShares 10 Year Investment Grade Corporate Bond ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IGLB News

IGLB iShares 10 Year Investment Grade Corporate Bond ETF